Journal article
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Annals of the rheumatic diseases, v 71(11), pp 1833-1838
01 Nov 2012
PMID: 22550315
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. Methods Data obtained after 52 weeks of treatment from two phase III trials (BLISS-52 and BLISS-76) comparing belimumab 1 and 10 mg/kg versus placebo, plus standard therapy, in 1684 autoantibody-positive patients were analysed post hoc for changes in British Isles Lupus Assessment Group (BILAG) and Safety of Estrogens in Lupus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA–SLEDAI) organ domain scores. Results At baseline, the domains involved in the majority of patients were musculoskeletal and mucocutaneous by both BILAG and SELENA–SLEDAI, and immunological by SELENA–SLEDAI. At 52 weeks, significantly more patients treated with belimumab versus placebo had improvement in BILAG musculoskeletal and mucocutaneous domains (1 and 10 mg/kg), and in SELENA–SLEDAI mucocutaneous (10 mg/kg), musculoskeletal (1 mg/kg) and immunological (1 and 10 mg/kg) domains. Improvement was also observed in other organ systems with a low prevalence (≤16%) at baseline, including the SELENA–SLEDAI vasculitis and central nervous system domains. Significantly fewer patients treated with belimumab versus placebo had worsening in the BILAG haematological domain (1 mg/kg) and in the SELENA–SLEDAI immunological (10 mg/kg), haematological (10 mg/kg) and renal (1 mg/kg) domains. Conclusions Belimumab treatment improved overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains. Less worsening occurred in the haematological, immunological and renal domains.
Metrics
Details
- Title
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
- Creators
- Susan Manzi - Allegheny Health NetworkJorge Sánchez-Guerrero - Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránJoan T Merrill - Oklahoma Medical Research FoundationRichard Furie - Northwell HealthDafna Gladman - Toronto Western HospitalSandra V Navarra - University of Santo Tomas HospitalEllen M Ginzler - SUNY Downstate Health Sciences UniversityDavid P D'Cruz - St Thomas' Hospital, London, UKAndrea Doria - University of PaduaSimon Cooper - Human Genome SciencesZ John Zhong - Human Genome SciencesDouglas Hough - Human Genome SciencesWilliam Freimuth - Human Genome SciencesMichelle A Petri - Johns Hopkins MedicineBLISS-52 Study Grp
- Publication Details
- Annals of the rheumatic diseases, v 71(11), pp 1833-1838
- Publisher
- British Medical Journal (BMJ)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000309654900013
- Scopus ID
- 2-s2.0-84867398973
- Other Identifier
- 991021934002104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Rheumatology